Clinical Trial Update: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/Phase 2 study of CT-1530 in relapsed or refractory B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Wal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• CT-1530

Snippet

Sponsor: Centaurus Biopharma Co., Ltd. | Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN